Plain-English translation of ยท
Phase 3 โ Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) โ a newer way to deliver cancer drugs directly to liver tumors using special beads โ works better and is safer than the traditional method (conventional TACE) in people with advanced liver cancer who have already had a shunt procedure. The medication is delivered through a thin tube placed in an artery, so the chemotherapy goes directly to the tumor rather than throughout your whole body.
After a shunt procedure is placed to treat liver complications, treatment options for advanced liver cancer become limited and risky. Early research suggests that the newer DEB-TACE method may deliver the chemotherapy more carefully and cause fewer side effects than the traditional approach in this specific situation, but doctors need to compare them directly to be sure.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will be randomly assigned to receive either the newer DEB-TACE or the traditional TACE treatment. The treatment involves a procedure where doctors place a thin tube into an artery and deliver chemotherapy beads directly to your liver tumor. The study will continue for about 4 years total, with 2 years for enrollment and 2 years of treatment and follow-up visits where doctors will monitor your health, check how well the cancer is responding, and track any side effects.
AI-generated summary from trial data ยท Jun 25, 2026 ยท Not medical advice
China